INTRODUCTION Erythropoiesis-stimulating agents and iron are commonly used in patients with chronic kidney disease with the aim of correcting anemia and maintaining stable hemoglobin levels. We analyzed pooled data from 13 studies with similar designs included in the Umbrella Continuous Erythropoietin Receptor Activator (C.E.R.A.) program to investigate the effects of continuous erythropoiesis r...

Anemia is the most common complication of chronic kidney disease (CKD) associated with reduced quality life and increased morbidity mortality. The purpose this review was to discuss management anemia in CKD. following topics are considered: prevalence anemia, symptoms, impact CKD, diagnosis, iron replacement therapy, erythropoiesis-stimulating agents.